EP1907856A2 - Inhibition de l'angiogenese a base de niveau d'expression du icam 1 ou junb - Google Patents

Inhibition de l'angiogenese a base de niveau d'expression du icam 1 ou junb

Info

Publication number
EP1907856A2
EP1907856A2 EP06762692A EP06762692A EP1907856A2 EP 1907856 A2 EP1907856 A2 EP 1907856A2 EP 06762692 A EP06762692 A EP 06762692A EP 06762692 A EP06762692 A EP 06762692A EP 1907856 A2 EP1907856 A2 EP 1907856A2
Authority
EP
European Patent Office
Prior art keywords
angiogenesis
disease
expression
subject
dna methyltransferase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06762692A
Other languages
German (de)
English (en)
Inventor
Manon Van Engeland
Arjan W. Griffioen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
OncoMethylome Sciences SA
Original Assignee
OncoMethylome Sciences SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0515471A external-priority patent/GB0515471D0/en
Application filed by OncoMethylome Sciences SA filed Critical OncoMethylome Sciences SA
Publication of EP1907856A2 publication Critical patent/EP1907856A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/16—Ophthalmology
    • G01N2800/164—Retinal disorders, e.g. retinopathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/20—Dermatological disorders

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention concerne des méthodes qui permettent de déterminer une angiogenèse associée à une maladie chez un sujet. Ces méthodes consistent à utiliser un échantillon d'essai approprié pour déterminer les niveaux d'expression d'au moins un gène choisi parmi junB and ICAM 1. Une baisse statistiquement significative du niveau (ou un faible niveau) d'expression d'un ou des deux gènes indique la présence d'une angiogenèse associée à une maladie chez le sujet. De préférence, l'échantillon d'essai comprend des cellules endothéliales. La méthode peut également consister à déterminer l'expression de THBSl et/ou de IGFBP3. Des méthodes de détermination de l'angiogenèse peuvent également consister à déterminer le taux d'histone acétylée, H3, dans la région d'activation du gène IGFBP3, dans un échantillon d'essai. Des compositions pharmaceutiques pouvant inhiber l'angiogenèse comprennent un inhibiteur de l'ADN méthyltransférase assorti d'un support pharmaceutiquement acceptable, et se présentent sous une forme appropriée pour un dosage métronomique. Ces compositions peuvent, en variante ou en complément, comprendre un constituant permettant le ciblage de cellules endothéliales. des Des méthodes de prévention ou d'inhibition de l'angiogenèse associée à une maladie chez un sujet consistent à administrer à ce dernier une quantité thérapeutiquement efficace d'un inhibiteur de l'ADN méthyltransférase. L'invention concerne en outre des régimes, des jeux ordonnés d'échantillons et des méthodes de criblage.
EP06762692A 2005-07-27 2006-07-19 Inhibition de l'angiogenese a base de niveau d'expression du icam 1 ou junb Withdrawn EP1907856A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US70258205P 2005-07-27 2005-07-27
GB0515471A GB0515471D0 (en) 2005-07-27 2005-07-27 Angiogenesis inhibition
PCT/EP2006/007092 WO2007017065A2 (fr) 2005-07-27 2006-07-19 Inhibition de l'angiogenese

Publications (1)

Publication Number Publication Date
EP1907856A2 true EP1907856A2 (fr) 2008-04-09

Family

ID=37546761

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06762692A Withdrawn EP1907856A2 (fr) 2005-07-27 2006-07-19 Inhibition de l'angiogenese a base de niveau d'expression du icam 1 ou junb

Country Status (2)

Country Link
EP (1) EP1907856A2 (fr)
WO (1) WO2007017065A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011109810A2 (fr) * 2010-03-05 2011-09-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. Procédés de prédiction de gliomes très avancés chez l'homme au moyen de gènes associés à la sénescence
PL2654758T3 (pl) 2010-12-22 2017-10-31 Idogen Ab Kompozycja zawierająca co najmniej dwa związki, która indukuje 2,3-dioksygenazę indolaminy (IDO) do leczenia zaburzenia autoimmunologicznego lub immunologicznego odrzucenia narządów
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
WO2018093797A1 (fr) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions et méthodes pour le traitement de l'angiogenèse aberrante
WO2019099560A1 (fr) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Inhibition de runx1 pour le traitement de la vitréorétinopathie proliférative et d'états associés à une transition épithéliale à mésenchymateuse
CN109771647A (zh) * 2019-01-28 2019-05-21 首都儿科研究所 Dna甲基转移酶抑制剂在构建神经管畸形小鼠模型中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400806A1 (fr) * 2002-09-18 2004-03-24 G2M Cancer Drugs AG Criblage pour inhibiteurs de l'histone déacétylase
ATE451115T1 (de) * 2003-07-07 2009-12-15 Van Andel Res Inst Hemmung der tumor-angiogenese durch eine kombination von thrombospondin-1 und hemmern des vaskulären endothel-wachstumsfaktors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007017065A3 *

Also Published As

Publication number Publication date
WO2007017065A2 (fr) 2007-02-15
WO2007017065A3 (fr) 2007-05-24

Similar Documents

Publication Publication Date Title
Fardi et al. Epigenetic mechanisms as a new approach in cancer treatment: An updated review
Sato et al. Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma
Dworkin et al. Epigenetic alterations in the breast: Implications for breast cancer detection, prognosis and treatment
Agrawal et al. DNA methylation in breast and colorectal cancers
Maier et al. Identifying DNA methylation biomarkers of cancer drug response
Melki et al. DNA methylation changes in leukaemia
Nagaraju et al. SPARC and DNA methylation: possible diagnostic and therapeutic implications in gastrointestinal cancers
Sato et al. The chemokine receptor CXCR4 is regulated by DNA methylation in pancreatic cancer
JP2008539731A (ja) 癌の診断及び治療のための組成物及び方法
US20120282167A1 (en) Method for predicting the sensitivity of a tumor to an epigenetic treatment
Sandhu et al. Epigenetic DNA hypermethylation in cholangiocarcinoma: potential roles in pathogenesis, diagnosis and identification of treatment targets
CA2600337A1 (fr) Marqueurs de melanome
EP1907856A2 (fr) Inhibition de l'angiogenese a base de niveau d'expression du icam 1 ou junb
Huang et al. Epigenetic modification and BRAF gene mutation in thyroid carcinoma
EP1836313A2 (fr) Procede d'estimation de patients souffrant d'une leucemie myeloide aigue
Gallagher et al. p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors
Huang et al. Identification of candidate epigenetic biomarkers for ovarian cancer detection
Shimizu et al. Methylated BNIP3 gene in colorectal cancer prognosis
Xu et al. SAMD14 promoter methylation is strongly associated with gene expression and poor prognosis in gastric cancer
Zhang et al. Epigenetics in the pathogenesis and treatment of cutaneous T-cell lymphoma
Bacalini et al. A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis
Ghadiri Moghaddam et al. Epigenetic insights in the diagnosis, prognosis, and treatment selection in CRC, an updated review
Lukosiute-Urboniene et al. Epigenetic regulation of APAF-1 through DNA methylation in pancreatic cancer
Pan et al. Study of the methylation patterns of the EGFR gene promoter in non-small cell lung cancer
Sasaki et al. Arg and DAP3 expression was correlated with human thymoma stage

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080201

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20080715

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090919